These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Dihydrolevobunolol is a potent ocular beta-adrenoceptor antagonist.
    Author: Woodward DF, Novack GD, Williams LS, Nieves AL, Potter DE.
    Journal: J Ocul Pharmacol; 1987; 3(1):11-5. PubMed ID: 2903201.
    Abstract:
    The ocular beta-adrenoceptor antagonist activity of dihydrolevobunolol (DHLB), the major ocular and systemic metabolite of levobunolol was investigated by determining its ability to block isoproterenol-induced ocular hypotension in normotensive rabbits. Topically-applied 0.001% and 0.01% DHLB virtually abolished the response to isoproterenol, indicating a beta-blocking potency similar to that of timolol. Thus, the ocular metabolism of levobunolol leads to the formation of a highly potent beta-adrenoceptor antagonist that may contribute to its clinical efficacy.
    [Abstract] [Full Text] [Related] [New Search]